QUELICIN recall in Canada: labelling differences
In plain language
This recall involves US-labelled QUELICIN (succinylcholine chloride injection) sold in Canada. It's being recalled because of differences in labelling compared to the Canadian product, which could lead to medication errors. Healthcare professionals should use the product as directed and review the updated prescribing information.
What to do
- Stop using the product immediately.
- Check model/serial numbers if provided.
- Return, repair, or dispose of it as instructed.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
QUELICIN (succinylcholine chloride injection USP) 200 mg/10 mL (20 mg/mL) vials
Why this matters
Medication error due to labelling differences
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Medication error due to labelling differences
What should consumers do?
Stop using the product immediately. Check model/serial numbers if provided. Return, repair, or dispose of it as instructed.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Medication error due to labelling differences
When was this product recalled?
This product was recalled on April 29, 2020.
Is the QUELICIN brand affected by this recall?
Yes, QUELICIN products are affected by this recall. This recall involves US-labelled QUELICIN (succinylcholine chloride injection) sold in Canada. It's being recalled because of differences in labelling compared to the Canadian product, which could lead to medication errors. Healthcare professionals should use the product as directed and review the updated prescribing information.